Inquis Medical, a Menlo Park, CA-based medical technology company specializing in advanced thrombectomy systems, raised $40M in Series B funding.
The round was led by Marshall Wace, with participation from existing investors, including ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond.
In connection with the Series B financing, Andrew D. Goldberg, MD, a portfolio manager at Marshall Wace, has joined Inquis Medical’s Board of Directors.
The company intends to us use the funds to complete its pivotal IDE trial, prepare for the commercial launch of the Aventus Thrombectomy System in 2025, and continue to advance its proprietary tissue-sensing platform.
Co-founded in 2020 by co-CEOs Vahid Saadat and Mojgan Saadat Inquis Medical is a clinical-stage medical device company focused on peripheral vascular innovations. The company is developing thrombectomy technology that offers physicians improved control and precision, enhances procedural efficiency, and minimizes blood loss.
Its flagship product, the Aventus Precision Thrombectomy System™, features proprietary tissue-sensing technology that provides operators with real-time information on the tissue composition in contact with the device. This innovative system offers enhanced precision and control during procedures.
